Kazunori Fujitaka

Last Updated :2020/09/14

Affiliations, Positions
Graduate School of Biomedical and Health Sciences(Medicine), Associate Professor or Lecturer
E-mail
fujikazuhiroshima-u.ac.jp

Basic Information

Major Professional Backgrounds

  • 2004/05/01, 2005/03/18, The University of Texas, postdoctoral fellow
  • 2005/04/01, 2005/09/30, Hiroshima University Hospital, Clinical Fellow
  • 2005/10/01, 2007/03/31, Hiroshima University Hospital, Research Associate
  • 2007/04/01, 2014/03/31, Hiroshima University Hospital, Assistant Professor
  • 2014/04/01, 2019/03/31, Hiroshima University, Institute of Biomedical & Health Sciences, Lecturer
  • 2019/04/01, Hiroshima University, Graduate School of Biomedical & Health Sciences , Lecturer

Educational Backgrounds

  • Hiroshima University, Graduate School, Division of Medical Sciences, Japan, 1999/04, 2002/03
  • Hiroshima University, Faculty of Medicine, Japan, 1987/04, 1993/03

Academic Degrees

  • Doctor of Philosophy in Medical Science, Hiroshima University

Educational Activity

  • 【Bachelor Degree Program】School of Medicine : Program of Medicine
  • 【Master's Program】Graduate School of Biomedical and Health Sciences : Division of Integrated Health Sciences
  • 【Doctoral Program】Graduate School of Biomedical and Health Sciences : Division of Biomedical Sciences : Program of Medicine

Research Fields

  • Medicine,dentistry, and pharmacy;Clinical internal medicine;Respiratory organ internal medicine

Affiliated Academic Societies

  • The Japanese Society of internal medicine
  • The Japanese Society of respiratory medicine
  • The japasese Society for Respiratory Endoscopy
  • The Japanese Society for Lung Cancer

Educational Activity

Course in Charge

  1. 2020, Undergraduate Education, Year, Clinical diagnosis and treatment I
  2. 2020, Undergraduate Education, First Semester, Internal Medicine Ⅱ
  3. 2020, Graduate Education (Doctoral Program) , First Semester, Practice of Oncology
  4. 2020, Graduate Education (Doctoral Program) , 1Term, Practice of Oncology
  5. 2020, Graduate Education (Master's Program) , Second Semester, General Clinical Medicine and Dentistry

Research Activities

Academic Papers

  1. A Case of Non-small Cell Lung Cancer Treated by an Anti-programmed Cell Death-1 Antibody without a Flare-up of Preexisting Granulomatosis with Polyangiitis., Intern Med, 58, 3129-3132
  2. Phase 2 Study of Afatinib Alone or Combined With Bevacizumab in Chemonaive Patients With Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations: AfaBev-CS Study Protocol., Clin Lung Cancer, 20, 134-138
  3. Interferon (Alpha, Beta and Omega) Receptor 2 Is a Prognostic Biomarker for Lung Cancer, PATHOBIOLOGY, 79(1), 24-33, 2012
  4. Characteristics of inspiratory and expiratory reactance in interstitial lung disease, RESPIRATORY MEDICINE, 107(6), 875-882, JUN 2013
  5. SK-216, an Inhibitor of Plasminogen Activator Inhibitor-1, Limits Tumor Progression and Angiogenesis, MOLECULAR CANCER THERAPEUTICS, 12(11), 2378-2388, NOV 2013
  6. Sglt gene expression in primary lung cancers and their metastatic lesions., Jpn.J.Cancer Res., 92(8), 874-9., 20010801
  7. KL-6 as an indicator for lymphocytic interstitial pneumonia (LIP) in a human T-lymphotrophic virus type-1 (HTLV-1) carrier., Ann Hematol, 81(8), 474-7., 20020801
  8. Usefulness of the modified lavage technique of Bingisser and KL-6 monitoring in a patient with pulmonary alveolar proteinosis., Intern Med, 41(5), 381-5., 20020501
  9. Carboplatin AUC and gamma-glutamylcysteine synthetase gene expression in peripheral mononuclear cells of lung cancer patients., Anticancer Reserch, 21(6A), 3933-6, 20011201
  10. Glutathione S-transferase-pi gene expression and platinum drug exposure in human lung cancer., Cancer Letter, 156(1), 93-9, 20000801
  11. Malignant paraganglioma arising from the posterior mediastinum: a case report and review of the literature., Hiroshima Journal of Medical Science, 48(4), 123-12, 19991201
  12. A case of pulmonary asbestosis presenting with temporal arteritis involving multiple medium-sized vessels., Mod Rheumatol, 18(1), 100-104, 20071201
  13. Usefulness monitoring of circulating KL-6 in patients with advanced non-small cell lung cancers treated with gefitinib therapy., International journal of cancer, 122(11), 2612-2620, 20080601
  14. Suplatast tosilate prevents bleomycin-induced pulmonary fibrosis in mice, J Pharmacol Exp Ther, 328(1), 55-61, 20090101
  15. Suppression of plasminogen activatior inhibitor-1 by RNA interference attenuates pulmonary fibrosis., Thorax, 65(4), 334-340, 20100401
  16. Erlotinib efficacy and cerebrospinal fluid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during gefitinib therapy., Cancer Chemother Pharmacol, 67(6), 1465-9, 20110101
  17. Regresson of a primary pulmonary adenocarcinoma after zoledronic acid monotherapy., Hiroshima J. Med. Sci, 60(1), 7-9, 20110301
  18. Phase I study docetaxel plus S-1 combination chemotherapy for recurrent non-small cell lung cancer., Oncology Letters, 2, 167-170, 20110101
  19. Change in serum KL-6 level from baseline is useful for predicting life-threatening EGFR-TKIs induced interstitial lung disease, Respir Res, 12, 97-107, 20110701
  20. Intra-airway administration of small interfering RNA targeting plasminogen activator inhibitor-1 attenuates allergic asthma in mice., Am J Physiol Lung Cell Mol Physiol, 301(6), L908-916, 20110901
  21. Association between expression of the MRP3 gene and exposure to platinum drugs in lung cancer, INTERNATIONAL JOURNAL OF CANCER, 93(4), 584-589, AUG 15 2001
  22. SGLT gene expression in primary lung cancers and their metastatic lesions, JAPANESE JOURNAL OF CANCER RESEARCH, 92(8), 874-879, AUG 2001
  23. Induction of cytochrome P450 3A4 by docetaxel in peripheral mononuclear cells and its expression in lung cancer, CANCER CHEMOTHERAPY AND PHARMACOLOGY, 48(1), 42-46, JUL 2001
  24. Syndrome of inappropriate secretion of ADH (SIADH) following cisplatin administration in a pulmonary adenocarcinoma patient with a malignant pleural effusion, INTERNAL MEDICINE, 40(10), 1020-1023, OCT 2001
  25. Carboplatin AUC and gamma-glutamylcysteine synthetase gene expression in peripheral mononuclear cells of lung cancer patients, ANTICANCER RESEARCH, 21(6A), 3933-3936, NOV-DEC 2001
  26. Usefulness of the modified lavage technique of Bingisser and KL-6 monitoring in a patient with pulmonary alveolar proteinosis, INTERNAL MEDICINE, 41(5), 381-385, MAY 2002
  27. A case of micronodular pneumocyte hyperplasia diagnosed through lung biopsy using thoracoscopy, RESPIRATION, 69(3), 277-279, MAY-JUN 2002
  28. KL-6 as an indicator for lymphocytic interstitial pneumonia (LIP) in a human T lymphotrophic virus type 1 (HTLV-1) carrier, ANNALS OF HEMATOLOGY, 81(8), 474-477, AUG 2002
  29. Investigating the relationship between serum thrombopoietin kinetics and the platelet-sparing effect: A clinical pharmacological evaluation of combined paclitaxel and carboplatin in patients with non-small cell lung cancer, ONCOLOGY REPORTS, 11(6), 1225-1231, JUN 2004
  30. Validation of the limited-sampling models for carboplatin AUC in combination chemotherapy with taxanes, ANTICANCER RESEARCH, 24(3B), 1911-1914, MAY-JUN 2004
  31. Neutropenic enterocolitis in lung cancer: A report of two cases and a review of the literature, INTERNAL MEDICINE, 44(5), 467-470, MAY 2005
  32. Usefulness of monitoring the circulating Krebs von den Lungen-6 levels to predict the clinical outcome of patients with advanced nonsmall cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors, INTERNATIONAL JOURNAL OF CANCER, 122(11), 2612-2620, JUN 1 2008
  33. A case of pulmonary asbestosis presenting with temporal arteritis involving multiple medium-sized vessels, MODERN RHEUMATOLOGY, 18(1), 100-104, FEB 2008
  34. Genetic ablation of the Bach1 gene reduces hyperoxic lung injury in mice: Role of IL-6, FREE RADICAL BIOLOGY AND MEDICINE, 46(8), 1119-1126, APR 15 2009
  35. Suppression of plasminogen activator inhibitor-1 by RNA interference attenuates pulmonary fibrosis, THORAX, 65(4), 334-340, APR 2010
  36. Erlotinib efficacy and cerebrospinal fluid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during gefitinib therapy, CANCER CHEMOTHERAPY AND PHARMACOLOGY, 67(6), 1465-1469, JUN 2011
  37. Change in serum KL-6 level from baseline is useful for predicting life-threatening EGFR-TKIs induced interstitial lung disease, RESPIRATORY RESEARCH, 12, JUL 26 2011
  38. Effect of increasing respiratory rate on airway resistance and reactance in COPD patients, RESPIROLOGY, 20(1), 87-94, JAN 2015
  39. MT95-4, a fully humanized antibody raised against aminopeptidase N, reduces tumor progression in a mouse model, CANCER SCIENCE, 106(7), 921-928, JUL 2015
  40. Histological Quantification of Gene Silencing by Intratracheal Administration of Dry Powdered Small-Interfering RNA/Chitosan Complexes in the Murine Lung, PHARMACEUTICAL RESEARCH, 32(12), 3877-3885, DEC 2015
  41. Inhibition of Plasminogen Activator Inhibitor-1 Attenuates Transforming Growth Factor-beta-Dependent Epithelial Mesenchymal Transition and Differentiation of Fibroblasts to Myofibroblasts, PLOS ONE, 11(2), FEB 9 2016
  42. MUC1 gene polymorphisms are associated with serum KL-6 levels and pulmonary dysfunction in pulmonary alveolar proteinosis, EUROPEAN RESPIRATORY JOURNAL, 42, 2013
  43. COMPARISON OF KL-6, SP-A, SP-D, 8-ISOPROSTANE, MMP-9, AND TIMP-1 AS SERUM BIOMARKERS FOR PATIENTS WITH COMBINED PULMONARY FIBROSIS AND EMPHYSEMA, RESPIROLOGY, 18, 58-58, 2013
  44. BRONCHOALVEOLAR LAVAGE CELLULAR PATTERN CAN PREDICT THE PROGNOSIS OF PATIENTS WITH CHRONIC HYPERSENSITIVITY PNEUMONITIS, RESPIROLOGY, 18, 80-80, 2013
  45. CHARACTERISTICS OF INSPIRATORY AND EXPIRATORY REACTANCE IN IDIOPATHIC PULMONARY FIBROSIS, RESPIROLOGY, 18, 137-137, 2013
  46. ANTITUMOR EFFECT OF A HUMANIZED ANTIBODY AGAINST AMINOPEPTIDASE N IN MOUSE TUMOR MODELS, RESPIROLOGY, 18, 151-151, 2013
  47. INCREASED OF RECEPTOR TYPE TYROSINE KINASE ROS1 IN INTERSTITIAL LUNG DISEASE, RESPIROLOGY, 18, 200-200, 2013
  48. A retrospective study comparing pemetrexed with taxanes as front-line cytotoxic chemotherapy for lung adenocarcinoma, ANNALS OF ONCOLOGY, 26, 123-123, 2015
  49. Comparative Study of Circulating MMP-7, CCL18, KL-6, SP-A, and SP-D as Disease Markers of Idiopathic Pulmonary Fibrosis, DISEASE MARKERS, 2016
  50. Long-term pulmonary complications of chemical weapons exposure in former poison gas factory workers, INHALATION TOXICOLOGY, 28(8), 343-348, JUL 2016
  51. Inhibition of PAI-1 Limits Tumor Angiogenesis Regardless of Angiogenic Stimuli in Malignant Pleural Mesothelioma, CANCER RESEARCH, 76(11), 3285-3294, JUN 1 2016
  52. Suplatast tosilate protects the lung against hyperoxic lung injury by scavenging hydroxyl radicals, FREE RADICAL BIOLOGY AND MEDICINE, 106, 1-9, MAY 2017
  53. AGER gene polymorphisms and soluble receptor for advanced glycation end product in patients with idiopathic pulmonary fibrosis, RESPIROLOGY, 22(5), 965-971, JUL 2017
  54. Chronic Intestinal Pseudo-obstruction and Orthostatic Hypotension Associated with Small Cell Lung Cancer that Improved with Tumor Reduction after Chemoradiotherapy, INTERNAL MEDICINE, 56(19), 2627-2631, 2017
  55. AGER rs2070600 polymorphism elevates neutrophil-lymphocyte ratio and mortality in metastatic lung adenocarcinoma, ONCOTARGET, 8(55), 94382-94392, NOV 7 2017
  56. Additional Octreotide Therapy to Sirolimus Achieved a Decrease in Sirolimus-refractory Chylous Effusion Complicated with Lymphangioleiomyomatosis, INTERNAL MEDICINE, 56(24), 3327-3331, 2017
  57. The extent of ground-glass attenuation is a risk factor of chemotherapy-related exacerbation of interstitial lung disease in patients with non-small cell lung cancer, CANCER CHEMOTHERAPY AND PHARMACOLOGY, 81(1), 131-139, JAN 2018
  58. FAM13A polymorphism as a prognostic factor in patients with idiopathic pulmonary fibrosis, RESPIRATORY MEDICINE, 123, 105-109, FEB 2017
  59. Nivolumab-induced severe pancytopenia in a patient with lung adenocarcinoma, LUNG CANCER, 119, 21-24, MAY 2018
  60. Aminopeptidase N/CD13 as a potential therapeutic target in malignant pleural mesothelioma, EUROPEAN RESPIRATORY JOURNAL, 51(5), MAY 1 2018
  61. Use of proton pump inhibitors is associated with increased mortality due to nosocomial pneumonia in bedridden patients receiving tube feeding., Geriatr Gerontol Int.
  62. Feasibility and Safety of CT-guided Intrathoracic and Bone Re-biopsy for Non-small Cell Lung Cancer., Anticancer Res.
  63. Bevacizumab with Single-agent Chemotherapy in Previously Treated Non-squamous Non-small-cell Lung Cancer: Phase II Study, IN VIVO, 32(5), 1155-1160, SEP-OCT 2018
  64. Use of proton pump inhibitors is associated with increased mortality due to nosocomial pneumonia in bedridden patients receiving tube feeding, GERIATRICS & GERONTOLOGY INTERNATIONAL, 18(8), 1215-1218, AUG 2018
  65. Intratracheal Administration of siRNA Dry Powder Targeting Vascular Endothelial Growth Factor Inhibits Lung Tumor Growth in Mice, MOLECULAR THERAPY-NUCLEIC ACIDS, 12, 698-706, SEP 7 2018
  66. Plasminogen activator inhibitor-1 serves an important role in radiation-induced pulmonary fibrosis, EXPERIMENTAL AND THERAPEUTIC MEDICINE, 16(4), 3070-3076, OCT 2018
  67. Feasibility and Safety of CT-guided Intrathoracic and Bone Re-biopsy for Non-small Cell Lung Cancer, ANTICANCER RESEARCH, 38(6), 3587-3592, 201806
  68. Alternate-day administration of S-1 for elderly patients with advanced non-small-cell lung carcinoma: A prospective feasibility study, MOLECULAR AND CLINICAL ONCOLOGY, 9(5), 539-544, 201811
  69. Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study, BMC CANCER, 18, 20181210
  70. Serial measurements of KL-6 for monitoring activity and recurrence of interstitial pneumonia with anti-aminoacyl-tRNA synthetase antibody A retrospective cohort study, MEDICINE, 97(49), 201812
  71. Anti-KL-6/MUC1 monoclonal antibody reverses resistance to trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity by capping MUC1, CANCER LETTERS, 442, 31-39, 2019
  72. High preoperative C-reactive protein level is a risk factor for acute exacerbation of interstitial lung disease after non-pulmonary surgery, MEDICINE, 98(5), 201902
  73. Cerebral embolism during edoxaban administration for venous thromboembolism in a patient with lung adenocarcinoma A case report, MEDICINE, 98(12), 201903
  74. Inhibition of PAI-1 limits chemotherapy resistance in lung cancer through suppressing myofibroblast characteristics of cancer-associated fibroblasts, JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 23(4), 2984-2994, 201904
  75. Performance Status Is a Risk Factor for Depression before the Diagnosis of Lung Cancer Patients, INTERNAL MEDICINE, 58(7), 915-920, 2019
  76. Suplatast tosilate reduces radiation-induced lung injury in mice through suppression of oxidative stress, FREE RADICAL BIOLOGY AND MEDICINE, 136, 52-59, 20190520
  77. Comparison of anti-aminoacyl-tRNA synthetase antibody-related and idiopathic non-specific interstitial pneumonia, RESPIRATORY MEDICINE, 152, 44-50, 201906
  78. A Prospective Cohort Study to Define the Clinical Features and Outcome of Lung Cancers Harboring HER2 Aberration in Japan (HER2-CS STUDY), CHEST, 156(2), 357-366, 201908
  79. Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer, RESPIRATORY INVESTIGATION, 57(5), 451-459, 201909
  80. C-C Motif Chemokine Ligand 15 May Be a Useful Biomarker for Predicting the Prognosis of Patients with Chronic Hypersensitivity Pneumonitis, RESPIRATION, 98(3), 212-220, 201909
  81. Chemotherapy-associated Acute Exacerbation of Interstitial Lung Disease Shortens Survival Especially in Small Cell Lung Cancer, ANTICANCER RESEARCH, 39(10), 5725-5731, 201910
  82. Non-small Cell Lung Cancer Treated by an Anti-programmed Cell Death-1 Antibody without a Flare-up of Preexisting Granulomatosis with Polyangiitis, INTERNAL MEDICINE, 58(21), 3129-3132, 2019
  83. Baseline High-Resolution CT Findings Predict Acute Exacerbation of Idiopathic Pulmonary Fibrosis: German and Japanese Cohort Study, JOURNAL OF CLINICAL MEDICINE, 8(12), 201912
  84. Albumin-globulin ratio is a predictive biomarker of antitumor effect of anti-PD-1 antibody in patients with non-small cell lung cancer, INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 25(1), 74-81, 202001
  85. Albumin-globulin ratio is a predictive biomarker of antitumor effect of anti-PD-1 antibody in patients with non-small cell lung cancer, INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 25(1), 74-81, 202001
  86. Treatment rationale and design of the PROLONG study: safety and efficacy of pembrolizumab as first-line therapy for elderly patients with non-small cell lung cancer, JOURNAL OF THORACIC DISEASE, 12(3), 1079-1084, 202003
  87. Serum high-mobility group box 1 is associated with the onset and severity of acute exacerbation of idiopathic pulmonary fibrosis, RESPIROLOGY, 25(3), 275-280, 202003
  88. Reduced endogenous secretory RAGE in blood and bronchoalveolar lavage fluid is associated with poor prognosis in idiopathic pulmonary fibrosis, RESPIRATORY RESEARCH, 21(1), 20200611

Invited Lecture, Oral Presentation, Poster Presentation

  1. Albumin-globulin ratio is a predictive biomarker of antitumor effect of anti-PD-1 antibody in patients with non-small cell lung cancer., Nakanishi Y, Masuda T, Sakamoto S, Yamaguchi K, Horimasu Y, Nakashima T, Miyamoto S, Iwamoto H, Fujitaka K, Hamada H, Hattori N., The 24th Congress of the Asian Pacific Society of Respirology (APSR 2019), 2019/11/14, Without Invitation, Hanoi
  2. The incidence and risk factors for acute exacerbation of interstitial lung disease after non-pulmonary surgery., Takao S, Masuda T, Yamaguchi K, Sakamoto S, Horimasu Y, Miyamoto S, Nakashima T, Iwamoto H, Fujitaka K, Hamada H, Hattori N., The 24th Congress of the Asian Pacific Society of Respirology (APSR 2019), 2019/11/14, Without Invitation, Hanoi
  3. Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer, Masuda T, Nakanishi Y, Yamaguchi K, Sakamoto S, Horimasu Y, Miyamoto S, Nakashima T, Iwamoto H, Fujitaka K, Hamada H, Hattori N., The 24th Congress of the Asian Pacific Society of Respirology (APSR 2019), 2019/11/14, Without Invitation, Hanoi
  4. Long-term pulmonary complications of sulfur mustard exposure in former poison gas factory workers, Nishimura Y, Iwamoto H, Ishikawa N, Hattori N, Horimasu Y, Ohshimo S, Fujitaka K, Kondo K, Hamada H, Awai K, Kohno N, 1st Asia Oceania Workshop of Pulmonary Functional Imaging, 2016/01, Without Invitation, Awaji
  5. MUC1 gene polymorphism and serum KL-6 in lung adenocarcinoma, Horimasu Y, Ishikawa N, Tanaka S, Iwamoto H, Ohshimo S, Fujitaka K, Hattori N, Hamada H, Kohno N., European Respiratory Society International Congress 2015, 2015/09, Without Invitation, Amsterdam, Netherlands
  6. Growth differentiation factor-15 (GDF-15) as prognostic factor in German patients with idiopathic pulmonary fibrosis, Ohshimo S, Hamai K, Bonella F, Yamaoka C, Horimasu Y, Iwamoto H, Ishikawa N, Fujitaka K, Murai H, Hamada H, Hattori N, Hirohashi N, Tanigawa K, Guzman J, Costabel U, Kohno N., American Thoracic Society International Conference 2015, 2015/05, Without Invitation, Denver, Colorado
  7. Comparative analysis of multiple gene polymorphisms for acute exacerbation of idiopathic pulmonary fibrosis, Ohshimo S, Yamaoka C, Horimasu Y, Iwamoto H, Fujitaka K, Hamada H, Hattori N, Hirohashi N, Tanigawa K, Bonella F, Guzman J, Costabel U, Kohno N., European Respiratory Society International Congress 2015, 2015/09, Without Invitation, Amsterdam, Netherlands
  8. HRCT Findings as a Predictive Factor for Acute Exacerbation of Idiopathic Pulmonary Fibrosis, Chihiro Yamaoka, Yasushi Horimasu, Hiroshi Iwamoto, Shinichiro Ohshimo, Kazunori Fujitaka, Hiroshi Murai, Noboru Hattori, Hironobu Hamada, Nobuoki Kohno, 2015/04, Without Invitation
  9. Growth differentiation factor-15 (GDF-15) as prognostic factor in Caucasians with idiopathic pulmonary fibrosis, Ohshimo S, Hamai K, Bonella F, Yamaoka C, Horimasu Y, Iwamoto H, Ishikawa N, Fujitaka K, Murai H, Hamada H, Hattori N, Hirohashi N, Tanigawa K, Guzman J, Costabel U, Kohno N., 2015/04, Without Invitation
  10. PAI-1 plays an important role in lung cancer progression through the association with differentiation of cancer-associated fibroblasts to myofibroblasts., Masuda T, Hattori N, Horimasu Y, Fujitaka K, Hamada H, American Thoracic society international Conference, 2016/05, Without Invitation, San Francisco
  11. PAI-1 plays an important role in radiatiopn-induced pulmonary fibrosis, Shioya S, Hattori N, Masuda T, Senoo T, Nakashima T, Iwamoto H, Fujitaka K, Kohno N, American Thoracic society international Conference, 2016/05, Without Invitation, San Francisco
  12. FAM13A Polymorphism as a Prognostic Factor in Patients with Idiopathic Pulmonary Fibrosis, Hirano C, Ohshimo S, Horimasu Y, Iwamoto H, Fujitaka K, Hamada H, Hattori N, Bonella F*, Guzman J, Costabel U, Kohno N, American Thoracic society international Conference 2016, 2016/05, Without Invitation, San Francisco
  13. FAM13A Polymorphism as a Prognostic Factor in Idiopathic Pulmonary Fibrosis: 1st Study in the Japanese Population, Hirano C, Ohshimo S, Horimasu Y, Iwamoto H, Fujitaka K, Hamada H, Hattori N, Bonella F, Guzman J, Costabel U, Kohno N, 2016/04, Without Invitation
  14. Decreased circulatory receptor for advanced glycation end-products is associated with poorer survival in patients with idiopathic pulmonary fibrosis, Yamaguchi K, Iwamoto H, Horimasu Y, Masuda T, Nakashima T, Miyamoto S, Ohshimo S, Fujitaka K, Hattori N, Mazur W, Kohno N, 2016/04, Without Invitation
  15. PAI-1 plays an important role in lung cancer progression through the association with differentiation of cancer-associated fibroblasts to myofibroblasts, Masuda T, Hattori N, Horimasu Y, Fujitaka K, Hamada H, 2016/10, Without Invitation
  16. Airway reversibility assessed by oscillometry in patients with asthma, Higaki N, Iwamoto H, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Fjitaka K, Hamada H, Hattori N, ERS, 1917/09/09, Without Invitation, Milan, Italy
  17. Extracorporeal membrane oxygenation for the treatment of acute exacerbation of interstitial lung diseases, Ohshimo S, Kida Y, Kyo M, Horimasu Y, Iwamoto H, Fjitaka K, Hamada H, Bonella F, Josune Guzman, Costabel U, Shime N, Hattori N, ERS International Congress 2017, 2017/09/09, Without Invitation
  18. Ground-glass opacity and fibrosis on HRCT as risk factors of acute exacerbation of IPF: an international multicenter study, Hirano C, Ohshimo S, Hilmar Kuehl, Daisuke Komoto, Horimasu Y, Iwamoto H, Hamada H, Hattori N, Costabel U, Kohno N, 2017/04/21, Without Invitation
  19. Vascular Endothelial Growth Factor Knockdown by Intratracheal administration of Small-Interfering RNA Dry Powder Inhibits Tumor Growth In a Mouse Lung Metastasis Model., Miwata K, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Iwamoto H, Fujitaka K, Hamada H, Hattori N, ATS 2018 International Conference, 2018/05/18, Without Invitation, San Diego
  20. Extent of the Honeycombing Area and the Presence of Traction Bronchiectasis are Risk Factors for Poorer Prognosis in Patients with Pleuroparenchymal Fibroelastosis., Namba M, Masuda T, Yamaguchi K, Sakamoto S, Horimasu Y, Miyamoto S, Nakashima T, Iwamoto H, Ohshimo S, Fujitaka K, Hamada H, Hattori N, ATS 2018 International Conference, 2018/05/18, Without Invitation, San Diego
  21. PAI-1 Influences the Effectiveness of Chemotherapy Through Its Association with Apoptosis in Cancer-Associated Myofibroblasts, Masuda T. Nakashima T, Namba M, Yamaguchi K, Sakamoto S, Horimasu Y, Miyamoto S, Iwamoto H, Fujitaka K, Hamada H, Hattori N, ATS 2018 International Conference, 2018/05/18, Without Invitation, San Diego